Table 1. Patient characteristics.
| Characteristica | No. (%) | |
|---|---|---|
| Age (years) | Median (range) | 65 (22–78) |
| Sex | Male | 56 (74) |
| Female | 20 (26) | |
| PS (ECOG) | 0 | 17 (22) |
| 1 | 50 (66) | |
| 2 | 9 (12) | |
| Initial disease location | Perihilar | 33 (43) |
| Distal | 43 (57) | |
| Pathologic T stage | T1 | 11 (15) |
| T2 | 33 (43) | |
| T3 | 32 (42) | |
| Pathologic N stage | N0 | 53 (70) |
| N1 | 22 (29) | |
| N/A | 1 (1) | |
| RM status | Negative | 52 (69) |
| Positive | 23 (30) | |
| N/A | 1 (1) | |
| Disease-free interval | ≤ 1 year | 39 (51) |
| > 1 year | 37 (49) | |
| Recurrence siteb | Resection site | 28 (37) |
| Lymph node | 41 (54) | |
| Anastomotic site | 14 (18) | |
| CA 19–9 (U/mL) | ≤ 37 | 36 (47) |
| > 37 | 38 (50) | |
| N/A | 2 (3) | |
| RT dose (BED) | ≥ 59 Gy | 68 (89) |
| < 59 Gy | 8 (11) | |
| Concurrent chemotherapy | Yes | 61 (80) |
| No | 15 (20) | |
| Additional chemotherapy after RT | Yes | 24 (32) |
| No | 52 (68) |
PS, performance status; ECOG, Eastern Cooperative Oncology Group; N/A, Not assessed; RM, resection margin; CA 19–9, Carbohydrate antigen 19–9; RT, radiation therapy; BED, biologically effective dose.
aThe characteristics were evaluated at the time of diagnosis of recurrence, except the initial disease treatment information including initial disease location, pathologic T stage, pathologic N stage, and RM status.
bSix patients showed both resection site and lymph node recurrence, and one patient showed both lymph node and anastomotic site recurrence.